BIVIHealthcare · Biotechnology

BIVI Stock Forecast: BioVie, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$1.91

+2.69% on the day

The 2 Wall Street analysts covering BioVie, Inc. hold a median 12-month price target of $5.26 — +175.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$16.5M

Ticker Nerd rank

22 / 100

Median analyst target

$5.26

Analysts covering

Total return, dividends reinvested

+36.4%

+48.1%

YTD

+64.7%

+25.7%

From 52W high

−15.9%

From 52W low

+98.1%

$0.96

$2.27

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

BIVI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioVie, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

22 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Volatility

Quality

Issuance

Momentum

Revisions

Growth

Value

Size (90): Smaller than most of the companies we track.

Value (15): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BIVI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BIVI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $5.00Median $5.26High $5.51

The green dot is the last close — the median target sits +175.1% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
1 July 2024	ThinkEquity	Initiates	Buy	$3.00
30 Nov 2023	Oppenheimer	Maintains	Outperform	—
22 Aug 2023	Cantor Fitzgerald	Reiterates	Overweight	—
18 July 2023	Cantor Fitzgerald	Reiterates	Overweight	—
17 May 2023	Cantor Fitzgerald	Reiterates	Overweight	—
17 May 2023	Oppenheimer	Reiterates	Outperform	—
14 Feb 2023	Oppenheimer	Reiterates	Outperform	—
28 Sept 2022	EF Hutton	Maintains	Buy	—
22 July 2022	Cantor Fitzgerald	Initiates	Overweight	—
17 Mar 2022	EF Hutton	Maintains	Buy	—
15 Mar 2022	Oppenheimer	Initiates	Outperform	—
30 Nov 2021	B. Riley Securities	Maintains	Buy	—
15 Jan 2021	B. Riley FBR	Initiates	Buy	—
15 Jan 2021	B. Riley Securities	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIVI appears on the weeks it earns a place.

Estimates

BIVI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

BioVie, Inc. (BIVI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.2×
Price / sales: —
Price / book: 1.4×
EV / EBITDA: −0.3×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −150.8%
Return on assets: −79.1%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BIVI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
BIVIBioVie, Inc.	$16.5M	22
CTXRCitius Pharmaceuticals, Inc.	$16.5M	20
PTNPalatin Technologies, Inc.	$16.5M	43
PBMPsyence Biomedical Ltd.	$16.5M	3
TPSTTempest Therapeutics, Inc.	$16.6M	36
ADILAdial Pharmaceuticals, Inc.	$16.3M	21
LPCNLipocine, Inc.	$16.8M	36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioVie, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BIVI news & analysis

BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript

Seeking Alpha · 13 Aug 2026neutral

Seeking Alpha published a transcript of BioVie Inc. (BIVI) discussing the mechanism of action of bezisterim and the design of its SUNRISE-PD Phase II trial. The item covers the company's presentation on these topics rather than reporting new results.

Why it matters — BIVI watchers would care because the discussion provides detail on bezisterim's mechanism and the SUNRISE-PD Phase II trial design, which is central to the company's Parkinson's disease development program.

Parkinson's drug developers are betting big on inflammation

Proactive Investors · 7 Aug 2026neutral

The article notes that Parkinson's drug developers are increasingly shifting focus from targeting the alpha-synuclein protein to targeting inflammation as a potential approach to slowing the disease.

Why it matters — For a BIVI watcher, this matters because the company's pipeline includes Parkinson's candidates that may be positioned within or affected by this broader industry shift toward inflammation-focused therapeutic strategies.

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

Proactive Investors · 6 Aug 2026positive

BioVie reported that its Parkinson's disease candidate bezisterim met the prespecified endpoints of the SUNRISE-PD Phase 2 trial. In the multicenter, randomized, double-blind, placebo-controlled study of early-stage Parkinson's patients not previously treated with carbidopa/levodopa, patients showed improvements in blood-based inflammatory markers and a range of clinical outcomes compared with placebo.

Why it matters — Meeting the Phase 2 endpoints marks a positive clinical development for bezisterim, BioVie's lead Parkinson's candidate, which is relevant to the company's pipeline outlook.

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

GlobeNewsWire · 6 Aug 2026positive

BioVie announced topline results from its Phase 2 SUNRISE-PD trial of bezisterim in early Parkinson's disease. Patients treated with bezisterim showed statistically significant improvements versus placebo on motor and non-motor symptoms, along with beneficial effects on plasma biomarkers of neurodegeneration and reduced biomarkers of neuro- and systemic-inflammation.

Why it matters — The statistically significant topline results for bezisterim are a key development for BioVie's Parkinson's disease program and its pipeline overall.

FAQ

Frequently asked questions about BIVI stock

What is the BIVI stock price forecast for 2026-2027?

The 2 Wall Street analysts covering BioVie, Inc. have a median 12-month price target of $5.26, with estimates ranging from $5 to $5.51. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BIVI stock a buy right now?

Of the 2 analysts covering BioVie, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioVie, Inc. 22 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BIVI?

As at 22 Aug 2026, BioVie, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will BIVI stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +175.1% from the last close, and Ticker Nerd's factor model ranks BioVie, Inc. 22 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BIVI stock forecast for 2030?

No analyst covering BioVie, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIVI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5.51 over the next 12 months.

How has BIVI stock performed over the past year?

BioVie, Inc. returned +25.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioVie, Inc. do?

BioVie Inc. is a biotechnology company focused on developing innovative treatments for liver diseases and neurodegenerative disorders.

What is the latest news on BIVI?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript". Seeking Alpha published a transcript of BioVie Inc. (BIVI) discussing the mechanism of action of bezisterim and the design of its SUNRISE-PD Phase II trial. The item covers the company's presentation on these topics rather than reporting new results.

Company

About BioVie, Inc.

BioVie Inc. is a biotechnology company focused on developing innovative treatments for liver diseases and neurodegenerative disorders. The company's primary objective is to address significant unmet medical needs with its cutting-edge therapeutic solutions. One of its notable areas of research includes therapies for Alzheimer's disease, where BioVie is advancing a novel drug candidate aimed at ameliorating cognitive decline associated with the condition. Additionally, BioVie is working on developing treatments for liver cirrhosis, particularly through leveraging its patented technologies. Headquartered in Carson City, Nevada, BioVie's work has the potential to make impactful contributions to the healthcare sector, especially in the fields of neurology and hepatology. In the financial markets, BioVie Inc. represents a key player within the biotechnology industry, offering investors exposure to high-risk, high-reward drug development endeavors. Its research initiatives and potential breakthroughs in medical treatments underscore its role in shaping future therapeutic landscapes.

CEO Mr. Cuong Viet Do M.B.A. · 13 employees · United States · https://bioviepharma.com